July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Simulation-based robotic surgery training boosts team confidence, communication
- Perioperative leaders gather at 2025 OR Manager Conference
- CMS launches 6-year model to curb wasteful Medicare spending with AI-driven reviews
- Report: Hospitals can cut anesthesia costs, burnout through tech-driven partnerships
- Study: One in four US healthcare workers faces food insecurity
- Digital decision aid boosts shared decision-making in knee replacement consultations
- CMS narrows surveys to immediate jeopardy, harm during shutdown
- Ambient AI turns burnout relief into 'hard ROI' at Seattle Children’s
- Robotics redefine cardiac surgery with precision, smaller incisions, new frontiers in AI and telesurgery
- Private equity bets big on outpatient cardiology as CMS boosts reimbursements
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement